TRAV1-2

Across TCGA pan-cancer cohorts, TRAV1-2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TRAV1-2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRAV1-2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAV1-2 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

KIRC, KIRP, and LUSC are the cancer types where TRAV1-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRAV1-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.176	<.001	10	view →
KIRP	Male	All	+0.657	.002	4	view →
LUSC	Male	II,III,IV	−0.624	.036	3	view →
BRCA	All	All	+0.235	.027	2	view →
COAD	All	All	−0.341	.015	1	view →
THCA	All	All	−0.286	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TRAV1-2–KIRC

Open the KIRC breakdown →